Clinical trial · Observational
WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
Whole Slide Image Based Deep Learning for Diagnosing the International Association for the Study of Lung Cancer Proposed Grading System of Lung Adenocarcinoma
NCT05925764CI-TRIAL-00081780recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the performance of a whole slide image based deep learning model for diagnosing the IASLC grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Artificial Intelligence | — | UNRESOLVED | — |
| IASLC Grading System | — | UNRESOLVED | — |
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Whole Slide Image | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole Slide Image based Deep Learning | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Agreement rate of the IASLC grading system
- timeFrame
- 2024.11.01-2024.12.31
- description
- Agreement rate between the deep learning model and pathologists in diagnosing the IASLC grade of lung adenocarcinoma.
Secondary outcomes (1)
- measure
- Agreement rate of the predominant subtypes
- timeFrame
- 2024.11.01-2024.12.31
- description
- Agreement rate between the deep learning model and pathologists in diagnosing the predominant growth patterns of lung adenocarcinoma.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ranging from 18-85 years old; 2. Pathological confirmation of primary lung adenocarcinoma after surgery; 3. Obtained written informed consent. Exclusion Criteria: 1. Multiple lung lesions; 2. Poor quality of whole slide images; 3. Mucinous adenocarcinomas and variants; 4. Participants who have received neoadjuvant therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.